[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610398":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":23,"centralContacts":27,"locations":33,"responsibleParty":49,"collaborators":18,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":18,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":18,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":18,"overallStatus":35,"whyStopped":18,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Medical University of South Carolina","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Methadone","ACTIVE_COMPARATOR","Patients will intraoperatively receive methadone 0.15mg\u002Fkg IV, based on ideal body weight.",[13],"Drug: Methadone",{"label":15,"type":16,"description":17,"interventionNames":18},"No Methadone","NO_INTERVENTION","Patients will NOT receive methadone.",null,[20],{"type":21,"name":9,"description":11,"armGroupLabels":22,"otherNames":18},"DRUG",[9],[24],{"name":25,"affiliation":5,"role":26},"Christopher Fatora, MD","PRINCIPAL_INVESTIGATOR",[28],{"name":29,"role":30,"phone":31,"phoneExt":18,"email":32},"Haley Nitchie, MHA","CONTACT","843-792-1869","nitchie@musc.edu",[34],{"facility":5,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Charleston","South Carolina","29425","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-79.93275,32.77632,{"lat":45,"lon":44},[48],{"name":29,"role":30,"phone":31,"phoneExt":18,"email":32},{"type":26,"investigatorFullName":25,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Assistant Professor-Faculty","100610398","phase-3-methadone-in-tha-for-post-op-pain-and-opioid-reduction-100610398",false,"NCT07227064","Methadone in THA for Post-op Pain and Opioid Reduction","Reduction of Post-op Pain and Opioid Consumption With the Addition of Methadone in Total Hip Arthroplasty: a Double-blind Randomized Control Trial","Inclusion\n\n* Ages 18-75 years of age\n* Undergoing elective primary total hip arthroplasty with mepivacaine in the spinal anesthesia\n\nExclusion\n\n* Allergy to methadone or mepivacaine\n* Severe liver disease defined as Child's Pugh Class C\n* End stage renal disease requiring dialysis\n* Known diagnosis of prolonged QT syndrome\n* Currently pregnant\n* Unable to provide written, informed consent\n* Non-English speaking","ALL","18 Years","75 Years",{"count":62,"type":63},162,"ESTIMATED","INTERVENTIONAL",[66],"PHASE3","This randomized, double-blind controlled trial investigates whether intraoperative intravenous methadone (0.15 mg\u002Fkg based on ideal body weight) reduces acute postoperative pain and opioid consumption in patients undergoing elective total hip arthroplasty under spinal anesthesia with mepivacaine. The primary outcome is patient-reported pain on a visual analog scale (VAS) 30-60 minutes after arrival in the post-anesthesia care unit (PACU). Secondary outcomes include opioid use, pain scores over time, incidence of nausea\u002Fvomiting, and quality of recovery. A total of 162 subjects will be enrolled at MUSC surgical sites.",[69,70],"Post Operative Pain","Total Hip Arthroplasty","2026-02-03",{"date":73,"type":74},"2026-02-05","ACTUAL",{"date":76,"type":74},"2026-01-12",{"date":78,"type":63},"2027-01-31",{"name":5,"class":6},1]